Related Experiment Video

Updated: May 31, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure

Thomas Schau1, Martin Seifert, Jürgen Meyhöfer

  • 1Department of Cardiology, Heart Center Brandenburg in Bernau, Berlin, Germany. t.schau@immanuel.de

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
|June 30, 2011
PubMed

Insights

Cardiac contractility modulation (CCM) is a novel therapy for heart failure. This study found CCM therapy did not adversely affect long-term survival in advanced heart failure patients.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Cardiac contractility modulation (CCM) is an emerging electrical therapy for patients diagnosed with congestive heart failure.
  • Previous clinical studies have established the safety of CCM and demonstrated improvements in exercise tolerance and quality of life.

Purpose of the Study:

  • To investigate the long-term impact of Cardiac Contractility Modulation (CCM) therapy on both cardiac and all-cause mortality in patients with advanced heart failure.

Main Methods:

  • A retrospective analysis was conducted on 54 consecutive advanced heart failure patients who received CCM therapy via an Optimizer system.
  • Patient data, including demographics, clinical status, and mortality, were collected and analyzed retrospectively.
  • Long-term outcomes were assessed through regular 3-month outpatient clinic follow-ups.

Main Results:

  • During the follow-up period, 44% of patients (24 out of 54) died, with 19 deaths attributed to cardiac causes.
  • Kaplan-Meier analysis revealed a median survival time of 992 days (33.1 months).
  • The observed all-cause mortality rate was accurately predicted by the Seattle Heart Failure Model.

Conclusions:

  • Cardiac contractility modulation (CCM) is a safe therapeutic option for advanced heart failure patients lacking other treatment alternatives.
  • While prior studies highlighted symptomatic benefits, this observational study provides initial evidence suggesting no negative impact of CCM on long-term survival.
  • CCM therapy may offer a viable treatment strategy for select advanced heart failure populations without compromising long-term prognosis.
Abstract

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.